1. Home
  2. WYY vs ALXO Comparison

WYY vs ALXO Comparison

Compare WYY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$4.91

Market Cap

68.2M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.15

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYY
ALXO
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.2M
68.3M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
WYY
ALXO
Price
$4.91
$2.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.67
$3.42
AVG Volume (30 Days)
46.2K
1.0M
Earning Date
03-03-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
54.35
31.02
EPS
N/A
N/A
Revenue
$142,571,749.00
N/A
Revenue This Year
$5.20
N/A
Revenue Next Year
$15.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
34.47
N/A
52 Week Low
$2.19
$0.41
52 Week High
$7.55
$2.66

Technical Indicators

Market Signals
Indicator
WYY
ALXO
Relative Strength Index (RSI) 43.53 52.41
Support Level $2.82 $1.41
Resistance Level $6.04 $2.27
Average True Range (ATR) 0.43 0.27
MACD 0.00 -0.05
Stochastic Oscillator 51.08 23.08

Price Performance

Historical Comparison
WYY
ALXO

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: